Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Steven A. Safren, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00050050
First received: November 20, 2002
Last updated: May 23, 2014
Last verified: May 2014

November 20, 2002
May 23, 2014
September 2001
August 2003   (final data collection date for primary outcome measure)
ADHD symptoms
Same as current
Complete list of historical versions of study NCT00050050 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
CBT for Residual ADHD Symptoms in Adults

This study will determine the effectiveness of cognitive behavioral therapy (CBT) in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in adults who have not responded to drug treatment.

Study hypothesis: CBT is an effective treatment for adult ADHD.

ADHD, previously believed to be a disorder of childhood, affects as many as 5 percent of adults. Adults with ADHD are at high risk for academic and occupational underachievement, relationship difficulties, and reduced quality of life. This study will determine whether CBT is more effective than drug therapy in treating ADHD symptoms in adults who have been resistant to previous drug therapies.

Participants will be randomly assigned to receive 12 to 15 weekly sessions of either CBT or drug therapy which may include new or previously taken drugs. Questionnaires will be used to assess participants' ADHD symptoms at study start and at study completion.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Attention Deficit Disorder With Hyperactivity
  • Behavioral: Cognitive behavioral therapy
  • Drug: Drug therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
August 2003
August 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult ADHD of at least moderate severity
  • On current drug therapy for ADHD

Exclusion Criteria:

  • Depression, panic disorder, bipolar disorder, organic mental disorders, psychotic disorders, or pervasive developmental disorders
  • Current substance abuse or dependence
  • IQ less than 90
  • Suicide risk
  • History of cognitive behavioral therapy
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00050050
R03 MH60940, R03MH060940, DSIR AT-AS
No
Steven A. Safren, Massachusetts General Hospital
Massachusetts General Hospital
National Institute of Mental Health (NIMH)
Principal Investigator: Steven A. Safren, PhD Massachusetts General Hospital
Massachusetts General Hospital
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP